CN1636053A - 造血细胞的植入 - Google Patents

造血细胞的植入 Download PDF

Info

Publication number
CN1636053A
CN1636053A CNA008041865A CN00804186A CN1636053A CN 1636053 A CN1636053 A CN 1636053A CN A008041865 A CNA008041865 A CN A008041865A CN 00804186 A CN00804186 A CN 00804186A CN 1636053 A CN1636053 A CN 1636053A
Authority
CN
China
Prior art keywords
cell
brain
purposes
disease
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA008041865A
Other languages
English (en)
Inventor
J·普里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reneuron Ltd
Original Assignee
Reneuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reneuron Ltd filed Critical Reneuron Ltd
Publication of CN1636053A publication Critical patent/CN1636053A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0647Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/04Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

造血干细胞的植入用于治疗损伤大脑。造血干细胞的大脑内植入可修复功能并且可适于Alzheimer’s病、帕金森病或Creuzfeld-Jacob病的治疗。

Description

造血细胞的植入
本发明涉及通过大脑内细胞的植入来克服感官、运动和/或认知缺陷,和关于这方面的细胞和药物。
有很多种疾病可引起感官、运动和/或认知缺陷并且当脑部遭受外伤时也会引起这种缺陷。例如,运动官能障碍就是帕金森症的一种症状。至今,大多数情况下,没有令人满意的可使用的治疗方法。
Bjornson等人,在科学(1999)283:534-537中,描述了神经干细胞产生各种血细胞型的能力,包括脊髓、淋巴和血细胞。据信神经干细胞包含表达其它隐性遗传信息所需要的适当的机制以响应正常刺激血干细胞的信号。由实验得到的结论是成人血系统含有强力的信号,其能“激活”神经干细胞。
造血细胞是包括白血球和红血球的全部血细胞的先代。已经有这样细胞植入的先例了,例如在WO-A-92/11355中,与血液疾病相关的包括镰刀细胞贫血症和血友病。在WO-A-92/11355和WO-A-93/18137中公开了培养和基因修饰造血干细胞的方法。
本发明部分地基于观察的结果,当植入进损伤或病变的大脑中时,造血于细胞通过作用能替代或补偿其它损伤或病变导致的的功能缺陷的表型明显响应损伤或病变的大脑中反应信号。
从本发明的使用中,在大脑的目标区域中,造血干细胞能区分出适于修复和补偿损伤或病变的细胞。用于植入的细胞不需要区分全部神经细胞的类型或表型。
可以对任何哺乳动物进行治疗但本发明特别涉及人类的治疗,尤其是治疗人细胞,及人细胞和细胞系。
当将本发明的细胞注入到人脑损伤的部分时,其能克服感官、运动和/或认知缺陷。此处使用的术语“损伤”包括功能的降低或失去。此术语也包括细胞损失。损伤是可以由包括物理外伤、组织缺氧不足(缺氧)、化学试剂引起的任何的形式,例如可以由药物滥用和疾病所引起。下列疾病和病理症状是疾病或导致感官、运动和/或认知缺陷的症状,其可由本发明来治疗:外部大脑伤害、击打、围产期的局部缺血,包括大脑瘫痪、Alzheimer’s、Pick’s和相关的痴呆性神经疾病、脑梗死、帕金森和帕金森型疾病、亨廷顿病、Korsakoffs病和Creuzfeld-Jacob病,也可根据本发明治疗健忘症,特别地,如心搏停止和冠状搭桥手术后引起的短暂球形局部缺血。
也可以在远离实际损伤的地方给予细胞,例如,可以从显示损伤的反侧方区域给予。
本发明提供造血干细胞以任意的分离的形式在制备用于治疗感官、运动和/或认知缺陷的药物中的用途。使用的药物包含造血干细胞。
本发明进一步提供了有条件存活的造血干细胞在制备用于治疗运动和/或认知缺陷的治疗药物中用途。使用的药物包括有条件存活的造血干细胞。
根据并用于本发明的条件存活干细胞得自克隆细胞系或是混合的种群。优选单克隆细胞系的细胞。可以使用从单细胞系得到的细胞或从两种或多种细胞系中得到混合细胞。
本发明进一步提供了包括根据发明的细胞和药用可接受载体的药物制备。
本发明基于把造血干细胞植入损伤的大脑来实现,此细胞令人吃惊地分化为另一种细胞形式,其能修复损伤和改善功能。分化出细胞的表型可与损伤或损失细胞的表型相同,但是,分化后的细胞也可以是不同的表型,或许多表型。不论如何,细胞作用于能对整合和损伤或损失的细胞进行功能整合和补偿的表型。我们已经发现,通过细胞有助于移动并找到损伤的组织。
使用干细胞意味着带有一个克隆细胞系的细胞可能修复大脑不同区域的损伤。这也意味着如果在一个给定的区域需要多于一个特别的细胞型来修复损伤则单细胞系将能分化出不同类型所需的细胞。
一定条件下活细胞在某种许可的条件下不会死亡,但是在非许可的条件下则会死亡。在这种情况下这就意味着通过有条件地使干细胞存活并且将其保持在许可的条件下,干细胞的生长可以在选择的阶段停止并且它们能在很长一段时间繁殖。存活条件的使用能使克隆细胞系在体外快速生长。如果把保存细胞的条件变化到不许可条件的话,则允许细胞继续生长。如果给细胞提供正确的条件的话,细胞将继续生长和分化。
通常是将致癌基因加入到细胞中来制备活细胞。因为要冒着在长时期内肿瘤形成的危险,所以在本发明中不优先使用这样的细胞。
在一定条件存活的细胞优点在于它们在需要的发展阶段中“冷冻”,当在允许的条件下它们易存活并繁殖力强,但是只要它们移入的环境为不许可的条件,将它们就可在移植中使用。在本发明情况下的细胞,应该选择常用于带来条件存活的基因,以便在大脑中出现的条件相应于不许可条件。
合适的条件存活致癌基因的例子是在US-A-5688692或WO-A-97/10329中描述的表达非DNA结合、对温度敏感的T抗原。
如果使用非存活细胞,那么可将其保存在体外培养基中,其中加入了如WO-A-92/11355和WO-A-93/18137公开的生长因子。
用于带来条件存活性的基因可以在从动物的骨髓提取出后合并到细胞中。
用于人体治疗的细胞优选源自人体细胞以减少免疫排斥的问题。这需要从人体骨髓中提取细胞。
但是,细胞不必非得是条件存活并且可以直接从被治疗的病人体内直接获得。
为了治疗病人,通常知道大脑中哪儿发生了损伤是很有帮助的。一旦确定了损伤的存在,不论其在一个独立的区域还是几个区域,都可以通过将细胞植入损伤的区域来进行治疗。但是在很多情况下,不能弄清被损组织的位置和/或类型或仅知道其很少的特性。例如,神经变性疾病可导致细胞不同类型广泛的损伤。治疗这样的损伤仍是可能的并且在造血干细胞的帮助下进行广泛的植入后找出被损组织。可将干细胞植入在一个位点,或优选在多个位点,并且能迁移到损伤的位点上,一旦到了那儿,在响应此处的微环境中,分化成为必须的表型从而改良或修复功能。
治疗后,可以对进行治疗后的病人使用感官、运动和/或认知缺陷试验进行监视和/或,如果需要的话,在大脑的选定区域中监视大脑活性。例如,用于认知功能的试验可以在植入之前或之后进行。
优选,治疗基本上能克服感官、运动和/或认知的缺陷(行为和或精神上的缺陷)。但是,那不总是可行的。根据本发明的治疗和用本发明的细胞、药物和药剂可以达到没有完全克服的功能改良。这样的改良是值得和有价值的。
使用的细胞数量将依据损伤组织的性质和程度而改变。典型地,用于植入细胞数量的范围约10万到几百万之间。治疗不必严格限定在单个植入。也可以进行附加的植入以进一步地改良功能。
为了研究在动物模型中的移植可采用Hodges等人在Pharmacology,Biochemistry and Behaviour(1997)56(4):763 780中描述的试验方法。一个实验利用大鼠,其中四容器咬合技术(4 VO),刺激人类心脏病,引起相关的限制并且对CA1锥状的背侧的海马细胞特定的损伤,同认知缺陷一样,其显示的困难在于如游泳池中水下不可见的平台。这提供了普通形式大脑损伤造成认知官能障碍的模型,即脑部供血的短暂丢失,例如可在心搏停止期间发生。
细胞植入人体和动物的方法在现有技术中是已知的并且在现有技术中有所描述。此处使用的术语“植入”包括在体外生长的细胞植入,和可以经过基因修饰的细胞植入,以及从其它有机体中提取的物质的植入。细胞可以利用定量微量调节注射器移入靶区,从而它们正常地分散在注射位点周围。也可将其植入大脑中的室间。如果植入到婴儿体内那么则分散到整个脑部。
用于此处的词组“大脑内移入”包括植入到大脑的任何部分。植入不限于大脑的前部和大部分。
本发明的应用现已单独在Chopp等人的Society for Neuroscience(1999),Vol.25,Abstract No.528.2中报道。摘要出版在本发明申请的优先权日之后并且详细描述了大鼠干细胞的大脑植入。
如摘要中描述的,成年小鼠进行中脑的动脉咬合(MCAo),并且将培养的造血干细胞(注入了生长因子)植入缺血纹状体中(MCAo后4天)。在植入过程中使用的细胞类型特定标记物用来区分供体细胞。结果显示供体细胞在植入过程中存活并且形态学上可在缺血纹状体中检测到,显示出神经原和星形胶质细胞的表型。
适当的赋形剂和载体对技术人员来说是容易找到的并且适于用在大脑内植入的配制方法也是明显的。
可以将本发明的干细胞进行基因转化以表达异种的基因产品。特别地,在损伤的位点上产生效果的治疗基因产品。在US-A-5958767中公开了合适的基因产品的例子。

Claims (9)

1.造血干细胞在制备用于治疗感官、运动和/或认知缺陷药物中用途。
2.如权利要求1的用途,用于损伤大脑的大脑内植入。
3.如权利要求1或2的用途,其中治疗指Alzheimer’s病、帕金森病、Korsakoffs病或Creuzfeld-Jacob病的治疗。
4.如前述任何一权利要求的用途,其中造血干细胞是有条件存活的。
5.如权利要求4的用途,其中细胞包括在35℃以上温度不表达的温敏致癌基因。
6.如权利要求5的用途,其中致癌基因表达SV40T-抗原。
7.如前述任何一权利要求的用途,其中将造血干细胞基因转化成表达治疗异种基因产品。
8.治疗感官、运动和/或认知缺陷的方法,其包括造血干细胞的大脑内植入。
9.如权利要求8所述的方法,其中细胞如权利要求4-7中任何一项所定义。
CNA008041865A 1999-02-24 2000-02-23 造血细胞的植入 Pending CN1636053A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9904281.4 1999-02-24
GBGB9904281.4A GB9904281D0 (en) 1999-02-24 1999-02-24 Transplantation

Publications (1)

Publication Number Publication Date
CN1636053A true CN1636053A (zh) 2005-07-06

Family

ID=10848438

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA008041865A Pending CN1636053A (zh) 1999-02-24 2000-02-23 造血细胞的植入

Country Status (20)

Country Link
EP (1) EP1161521B1 (zh)
JP (1) JP4716575B2 (zh)
KR (1) KR20020000216A (zh)
CN (1) CN1636053A (zh)
AT (1) ATE237680T1 (zh)
AU (1) AU762763B2 (zh)
CA (1) CA2361401A1 (zh)
CZ (1) CZ20012651A3 (zh)
DE (1) DE60002185T2 (zh)
DK (1) DK1161521T3 (zh)
ES (1) ES2193938T3 (zh)
GB (1) GB9904281D0 (zh)
HK (1) HK1041284B (zh)
HU (1) HUP0105168A3 (zh)
NO (1) NO20014091D0 (zh)
PL (1) PL350297A1 (zh)
PT (1) PT1161521E (zh)
RU (1) RU2216336C2 (zh)
SK (1) SK11232001A3 (zh)
WO (1) WO2000050568A2 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101495623B (zh) * 2006-03-24 2013-09-11 儿童医疗中心有限公司 调节造血干细胞生长的方法
CN114934072A (zh) * 2022-05-18 2022-08-23 华中科技大学同济医学院附属协和医院 一种人心脏瓣膜间质细胞系的永生化构建方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518606D0 (en) 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
DK1183035T3 (en) * 1999-05-14 2015-03-09 Ford Henry Health System BONE MARROW TRANSPLANT TREATMENT stroke
US8017112B2 (en) 1999-05-14 2011-09-13 Henry Ford Health System Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
CA2473503C (en) * 2002-01-14 2010-01-05 The Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation
KR20050086606A (ko) * 2002-11-15 2005-08-30 가부시키가이샤 상가쿠렌케이키코큐슈 장기의 재생 방법
ES2294650T3 (es) 2004-09-30 2008-04-01 Reneuron Limited Linea celular.
RU2283119C1 (ru) * 2005-03-29 2006-09-10 Андрей Степанович БРЮХОВЕЦКИЙ Препарат аутологичных гемопоэтических стволовых клеток, способ его получения, криоконсервации и использования для лечения травматической болезни центральной нервной системы
US7569545B2 (en) * 2005-05-20 2009-08-04 Academia Sinica Methods of increasing neurotrophic factor expression
MX2009004164A (es) 2006-10-20 2009-10-13 Childrens Medical Center Metodo para aumentar la regeneracion de tejido.
CA2736018C (en) 2008-09-16 2015-11-03 Stephanie Merchant Compositions for treating or delaying the onset of hair loss
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
GB0902034D0 (en) 2009-02-06 2009-03-11 Reneuron Ltd Method
AU2012245269B2 (en) * 2011-04-20 2016-09-29 The Regents Of The University Of California Method for combined conditioning and chemoselection in a single cycle
PT2785834T (pt) 2011-12-02 2020-11-13 Fate Therapeutics Inc Composição de células estaminais melhorada
EP3381456A1 (en) 2011-12-02 2018-10-03 Fate Therapeutics, Inc. Improved methods for treating ischemia
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
RU2647429C1 (ru) * 2017-02-06 2018-03-15 Федеральное государственное автономное образовательное учреждение высшего образования "Дальневосточный федеральный университет" (ДВФУ) Биомедицинский клеточный препарат
RU2720002C1 (ru) * 2018-12-28 2020-04-23 Андрей Степанович БРЮХОВЕЦКИЙ Биомедицинский клеточный продукт для лечения нервных болезней и психических расстройств, способ его получения и его применение

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
CA2131368A1 (en) * 1992-03-04 1993-09-16 Chu-Chih Shih Culturing of hematopoietic stem cells and their genetic engineering
EE03509B2 (et) * 1995-06-27 2015-02-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Stabiilsed ravimikompositsioonid kandegaasita aerosoolide saamiseks
GB9518606D0 (en) * 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
IL128348A (en) * 1996-08-19 2008-08-07 Univ Massachusetts Method of producing embryonic or stem like cell lines by transplantation of cell nuclei from animal or mammal, such cells and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101495623B (zh) * 2006-03-24 2013-09-11 儿童医疗中心有限公司 调节造血干细胞生长的方法
CN114934072A (zh) * 2022-05-18 2022-08-23 华中科技大学同济医学院附属协和医院 一种人心脏瓣膜间质细胞系的永生化构建方法
CN114934072B (zh) * 2022-05-18 2023-10-20 华中科技大学同济医学院附属协和医院 一种人心脏瓣膜间质细胞系的永生化构建方法

Also Published As

Publication number Publication date
CZ20012651A3 (cs) 2002-01-16
RU2216336C2 (ru) 2003-11-20
HUP0105168A2 (hu) 2002-05-29
GB9904281D0 (en) 1999-04-21
JP2002537406A (ja) 2002-11-05
HUP0105168A3 (en) 2003-12-29
DK1161521T3 (da) 2003-06-16
ATE237680T1 (de) 2003-05-15
ES2193938T3 (es) 2003-11-16
SK11232001A3 (sk) 2002-01-07
PL350297A1 (en) 2002-12-02
HK1041284A1 (en) 2002-07-05
DE60002185T2 (de) 2003-12-18
DE60002185D1 (de) 2003-05-22
HK1041284B (zh) 2003-10-03
NO20014091L (no) 2001-08-23
AU2682100A (en) 2000-09-14
WO2000050568A2 (en) 2000-08-31
CA2361401A1 (en) 2000-08-31
KR20020000216A (ko) 2002-01-05
PT1161521E (pt) 2003-08-29
EP1161521A2 (en) 2001-12-12
EP1161521B1 (en) 2003-04-16
JP4716575B2 (ja) 2011-07-06
WO2000050568A3 (en) 2000-12-07
AU762763B2 (en) 2003-07-03
NO20014091D0 (no) 2001-08-23

Similar Documents

Publication Publication Date Title
CN1636053A (zh) 造血细胞的植入
Aebischer et al. Intrathecal delivery of CNTF using encapsulated genetically modifiedxenogeneic cells in amyotrophic lateral sclerosis patients
ES2435080T3 (es) Procedimiento de expansión de células madre adultas de sangre, en particular sangre periférica, y aplicación relativa en el campo médico
US10993969B2 (en) Methods and materials for treating nerve injuries and neurological disorders
Hitchcock et al. Stereotactic implantation of fetal mesencephalon
DE69835591T2 (de) Induktoren für immuntoleranz
Haseltine Regenerative medicine
Rab et al. Free functional muscle transplantation for facial reanimation: experimental comparison between the one-and two-stage approach
Sagen Cellular therapies for spinal cord injury: what will the FDA need to approve moving from the laboratory to the human?
Sutar et al. An Overview of Stem Cell Therapy
Jeffery et al. Bridging the divide: spinal cord repair by cellular transplantation‐from research laboratory to therapeutic application
Jose Multiple sclerosis: can Schwann cells wrap it up?
RU2160112C1 (ru) Способ приготовления клеточного трансплантата из фетальных тканей
Bunge What types of bridges will best promote axonal regeneration across an area of injury in the adult mammalian spinal cord?
Björklund The use of neural stem cells for gene therapy in the central nervous system
Yinon et al. Physiological studies in deafferented visual cortex cells of cats following transplantation of fetal xenografts from the rat's cortex
Stepanov et al. Xenotransplantation of stem/progenitor cells from human fetal brain to adult rats with spinal trauma
Mackay-Sim Stem cells: a beginner's guide.
Barres et al. Purification of rat retinal ganglion cells by immunopanning
Stein Practical and theoretical issues in the uses of fetal brain tissue transplants to promote recovery from brain injury
Ahmed et al. Pharmaceutical sciences
Schwartz et al. Therapeutic uses of stem cells
Tator 3 Spinal Cord Regeneration
Slepchuk Is Stem Cell Transplantation a Practical Treatment for Macular Degeneration?
Gupta An overview on stem cell as a genetic medicine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication